Clinical Trial Search

Primary: Dose-limiting Toxicities (DLT) of Topical Compound 31543 — 0; 0; 0; 0 Participants

Primary: Hair Preservation — 2; 3 Participants

Primary: Efficacy of PenguinTM Cold-caps for Prevention or Reduction of CIA — 4; 3; 3 Participants

Primary: Change in Development of Hair Loss — 30; 0; 0; 4 Participants

Primary: The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF) — 3.10; 3.10; 1.72; 3.50 score on a scale

Primary: Evaluation of the Occurrence of Nail Toxicity of Grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 Evaluated at 8 Weeks Post Infusion of Docetaxel. — 26; 49…

Primary: Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation) — 32 participants

Primary: Number of Participants With Progression-free Survival — 17 Participants

Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053

Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants

Primary: Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site — 76.7 percentage of participants

Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 88.9; 27.8 Percentage of…

Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants

Primary: Overall Complete Response Rate — 10; 10 percentage of participants

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Progession Free Survival — 85.7 % of participants without progression

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg

Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants

Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation

Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale

Primary: Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group — 300; 250 ug/mL*hr

Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants

Primary: Participants With Mucositis and Hematological Toxicities With the Addition of Radioprotector Amifostine — 16 participants

Primary: Number of Participants With Adverse Events — 9; 20 Participants

Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants

Primary: Primary Site Complete Response Rate — 6; 4 Participants

Primary: Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days — 57; 29 Participants — p=0.7186

Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68

Primary: CR Rate — 42; 55; 134; 18 Participants